The Multiple Myeloma Hub spoke with Ravi Vij, Washington University, St. Louis, US. We asked, What combination regimens including bispecific T-cell engagers (BiTEs) are being evaluated for the treatment of relapsed/refractory multiple myeloma (RRMM)? 

 During this interview, Ravi Vij discussed combination strategies involving BiTEs for the treatment of RRMM. Vij highlighted the movement of B-cell maturation antigen (BCMA)- and G-protein-coupled receptor family C group 5 member D (GPRC5D)-directed BiTEs into earlier lines of therapy and their integration into regimens with established agents such as daratumumab, pomalidomide, and lenalidomide. In addition, Vij noted that novel FcRH5-directed BiTEs such as cevostamab are being investigated in combination regimens, with early-phase studies reporting high response rates, including complete responses. Vij concluded that while results are encouraging, concerns remain regarding increased risk of infections and the need for more mature data on durability of response and progression-free survival prior to regulatory approvals of new agents or combinations.

This educational resource is independently supported by Roche. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource. 

Hosted on Acast. See acast.com/privacy for more information.